OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PRAX
Praxis Precision Medicines, Inc.
There isn't enough reported data to score PRAX yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRAX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PRAX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
PRAX PE Valuation
PRAX has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PRAX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PRAX's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over PRAX on earnings quality, reporting a profit while its opponent remains loss making.
PRAX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$12.82 | +$0.02 |
| Q2 2026 | -$12.95 | -$0.72 |
| Q1 2026 | -$13.39 | -$2.73 |
| Q4 2025 | -$13.48 | -$3.27 |
| Q3 2023 | -$33.45 | +$43.65 |
| Q2 2023 | -$45.15 | +$32.55 |
| Q1 2023 | -$57.60 | +$13.50 |
| Q4 2022 | -$69.60 | -$10.50 |
PRAX is still losing money, but far less than before: $12.82 per share over the past year, against $77.70 at its worst in mid-2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the stronger quarterly revenue trend. Revenue is up 72% for OSCR versus down 100% for PRAX.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
PRAX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $7.5M | +1349% |
| Q3 2024 | $302K | -35% |
| Q2 2024 | $357K | -54% |
| Q1 2024 | $431K | -37% |
PRAX's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -857% | +4542 points |
| Q3 2024 | -18820% | -13367 points |
| Q2 2024 | -10501% | -6025 points |
| Q1 2024 | -9718% | -4141 points |
| Q4 2023 | -5399% | N/A |
| Q3 2023 | -5452% | N/A |
| Q2 2023 | -4476% | N/A |
| Q1 2023 | -5577% | N/A |
PRAX's operating margin was −857% last quarter, up 4542 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over PRAX on cash generation, producing positive trailing cash flow while its opponent burns cash.
PRAX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$83.3M | -$18.2M |
| Q1 2026 | -$86.2M | -$33.2M |
| Q3 2025 | -$65.1M | -$37.6M |
| Q1 2025 | -$53M | -$32.2M |
| Q3 2024 | -$27.5M | -$4.3M |
| Q2 2024 | -$27.3M | +$3.9M |
| Q1 2024 | -$20.9M | +$12M |
| Q4 2023 | -$23.9M | +$4.9M |
PRAX has burned cash in almost every quarter: −$324M over the past year, against −$173M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PRAX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +47K shares |
| 1 year | +33% | +7.2M shares |
| 3 years | +528% | +24.5M shares |
| 5 years | +953% | +26.4M shares |
PRAX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | $30M |
| Q4 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
PRAX Net Leverage
PRAX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PRAX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.5 | Neutral |
| Stochastic | 38.0 | Neutral |
PRAX's weekly RSI is 54 (neutral) and its Stochastic is 38 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PRAX PE vs Healthcare Sector
PRAX has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
PRAX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $277.4 | 17% above |
| 20 week MA | $312.2 | 4% above |
| 50 week MA | $309.1 | 5.1% above |
| 100 week MA | $189.4 | 71% above |
| 200 week MA | $113.8 | 185% above |
PRAX is in an uptrend: it's above all five of its weekly moving averages, and 185% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PRAX on returns for 2026, with the stronger performance.
PRAX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $417.0 | $790.1 | +89% |
| 2021 | $790.1 | $309.2 | -61% |
| 2022 | $309.2 | $36.3 | -88% |
| 2023 | $36.3 | $22.3 | -39% |
| 2024 | $22.3 | $77.0 | +246% |
| 2025 | $77.0 | $269.0 | +249% |
| 2026 YTD | $269.0 | $324.8 | +21% |
PRAX's yearly returns have swung widely, from +249% in 2025 to −88% in 2022. It's up 21% so far in 2026.